Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Grübler, MR; Delgado, G; Kleber, M; Hartaigh, BÓ; de, Boer, RA; Verheyen, N; Keppel, M; Schmid, J; Siontis, GC; Räber, L; Pieske, B; Pilz, S; Tomaschitz, A; März, W.
Effect of Galectin 3 on Aldosterone-Associated Risk of Cardiovascular Mortality in Patients Undergoing Coronary Angiography.
Am J Cardiol. 2020; 127:9-15
Doi: 10.1016/j.amjcard.2020.04.017
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Führende Autor*innen der Med Uni Graz
- Grübler Martin
- Co-Autor*innen der Med Uni Graz
- Keppel Martin Helmut
- März Winfried
- Pieske Burkert Mathias
- Pilz Stefan
- Schmid Johannes
- Tomaschitz Andreas
- Verheyen Nicolas Dominik
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Recent experimental studies have suggested that galectin-3 has an interaction with aldosterone, and modifies its adverse effects. We therefore aimed to elucidate whether the relationship between plasma aldosterone concentrations (PACs) and long-term fatal cardiovascular (CV) events would depend on plasma galectin-3 levels. A total of 2,457 patients (median age: 63.5 [interquartile range (IQR) = 56.3 to 70.6] years, 30.1% women) from the LUdwigshafen RIsk and Cardiovascular Health study, with a median follow-up of 9.9 (IQR = 8.5 to 10.7) years, were included. We tested the interaction between aldosterone and galectin-3 for CV-mortality using a multivariate Cox proportional hazard model, reporting hazard ratios (HRs) with 95% confidence intervals (95%CIs). Adjustments for multiple CV risk factors as well as medication use were included. Mean PAC was 79.0 (IQR = 48.0 to 124.0) pg/ml and there were 558 (16.8%) CV deaths. There was a significant interaction between PAC and galectin-3 (p = 0.021). When stratifying patients by the median galectin-3, there was a significant association between aldosterone and CV-mortality for those above (HR per 1 standard deviation = 1.14; 95%CI [1.01 to 1.30], p = 0.023), but not below the cut-off value (HR per 1 standard deviation = 1.00; 95%CI [0.87 to 1.15], p = 0.185). In conclusion, the current study demonstrates for the first time a modifying effect of galectin-3 on the association between aldosterone and CV-mortality risk in humans. These findings indicate that galectin-3 is an intermediate between aldosterone and adverse outcomes.
- Find related publications in this database (using NLM MeSH Indexing)
- Aged - administration & dosage
- Aldosterone - blood
- Cardiovascular Diseases - blood, diagnosis, mortality
- Coronary Angiography - methods
- Coronary Artery Disease - blood, diagnosis, mortality
- Female - administration & dosage
- Follow-Up Studies - administration & dosage
- Galectin 3 - blood
- Germany - epidemiology
- Humans - administration & dosage
- Male - administration & dosage
- Middle Aged - administration & dosage
- Prognosis - administration & dosage
- Prospective Studies - administration & dosage
- Risk Assessment - methods
- Risk Factors - administration & dosage
- Survival Rate - trends